This report provides all the information you require to better understand Valeant and its partnering interests and activities over the past seven years

Valeant Pharmaceuticals is a top pharmaceutical company based in Montreal, Quebec, Canada

Allergan is currently the subject of much speculation as Valeant Pharmaceuticals looks to acquire it. Valeant Pharmaceuticals, well known for building its company via acquisitions, put in a $46 billion bid one week ago to acquire Californian based botox maker Allergan.

Drugmakers Valeant Pharmaceuticals International Inc , Actavis Plc and Mylan Inc have all expressed interest in buying Pfizer’s branded generics business, but no active discussions are going on at this time, according to three people close to the matter.

Valeant Pharmaceuticals International continues to be on the lookout for other specialty areas after its blockbuster deal to buy eye-care giant Bausch & Lomb

Valeant, a top pharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years

Valeant has announced 30 M&A deals since 2005, with the lead deals being the acquisition of Medicis, Biovail

Valeant announced over 55 partnering / licensing deals since 2005, with 11 deals in 2012 alone. Analysis of the partnering deals shows a strong emphasis on partnerships in dermatology, central nervous system, oncology and infective diseases

Valeant is a top pharma company active in partnering, licensing and M&A in generic pharmaceuticals

Individuals familar with the matter state that merger deal stalled on details of Actavis valuation

Valeant has responded to Merz’s acquisition offer for Obagi Medical Products with a higher offer. Will Merz respond?

Valeant increased the offer price to acquire all the outstanding common stock of Salix from $158.00 per share to $173.00 per share

Valeant Pharmaceuticals have entered into a definitive agreement under which Valeant will acquire all of the outstanding common stock of Salix

Big pharma, Valeant Pharmaceuticals International, has completed the private placement financing of senior unsecured notes due 2023, for gross proceeds of USD1 billion.

Valeant Pharmaceuticals has extended the acquisition period for Allergan.

Akorn has sold its subsidiary, ECR Pharmaceuticals, to Valeant Pharmaceuticals for $41 million in cash and assumption of certain liabilities.

Valeant Pharmaceuticals and Pershing Square plan to approach the shareholders of Allergan for a hostile takeover.

Valeant Pharmaceuticals International has entered into an agreement with Nestle to sell all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport owned or held by Valeant for $1.4 billion in cash.

Actavis has entered into an agreement with Valeant Pharmaceuticals to settle all outstanding patent litigation related to Actavis’ generic version of Acanya (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/2.5%.

Allergan announced that its Board of Directors has unanimously rejected the unsolicited proposal announced by Valeant Pharmaceuticals International, Inc.  on April 22, 2014.

Big Pharma, Valeant Pharmaceuticals International Team Up To Make $45.6 Billion Allergan Bid.